While we saw no drama in the reported numbers, we have a few key take-aways from the conference call, which has resulted in us raising our ‘23e EBIT by 3%. 1) The Vetio order visibility looks even stronger than we thought, with Vetio North having a higher share of development revenues likely to turn into manufacturing during 2022-2023. On the back of this, we raise our organic growth assumptions for the company by 5pp in H2’22-‘23e to c. 20%. 2) Insourcing synergies are likely to materialise earlier than our initial expectations. On the conference call, management stated that they target 50% of US production to be insourced in 12 months, indicating faster synergies in Rx than our earlier expectations. On the back of this, we raise our ’21-‘23e sales and EBIT by 0-4% and 1-3%, respectively. 3) The company will review its financial targets during H2. While we believe the margin target is likely to stay, the review could result in a bump to the sales level, which now implies a 20% CAGR on our 2023 estimates.
Trading at 41x EV/EBIT 2023e
On our updated estimates, the Swedencare share is trading at a ‘21e-‘23e EV/EBIT of 72-41x. This corresponds to the share trading 35-25% above animal health peers and 34-29% above Nordic ingredient brand peers. We furthermore note that the newly IPOed Vimian is trading at a ‘21e-‘23e EV/EBITA of 68-43x.
Aktuellt
SENASTE
